Sone-190

Most neuro‑degenerative diseases are characterized by the accumulation of misfolded proteins. In FTD and a subset of amyotrophic lateral sclerosis (ALS) cases, the RNA‑binding protein TAR DNA‑binding protein 43 (TDP‑43) aggregates in neuronal cytoplasm, disrupting RNA metabolism and triggering cell death.

SO​NE‑190 was designed to stabilize the native conformation of TDP‑43 and prevent its pathological polymerisation. By binding to a newly identified allosteric pocket on the RNA‑recognition motif (RRM) domain, the compound: SONE-190

The molecule belongs to a novel chemotype of spiro‑cyclopropane‑based inhibitors. Key attributes include: | Metric | Current Situation | Projected Change

| Property | Value (Pre‑clinical) | |----------|----------------------| | Molecular weight | 378 Da | | LogP | 2.1 (balanced lipophilicity) | | Brain/plasma ratio (rat) | 1.3 | | Oral bioavailability | ~65% | | Half‑life (human) | 12 h (dose‑proportional) | SONE-190

These characteristics give SONE‑190 good oral exposure and robust CNS penetration, a combination that has eluded many past attempts at targeting TDP‑43.

| Metric | Current Situation | Projected Change with SONE‑190 | |--------|-------------------|-------------------------------| | Time to diagnosis | Average 2–3 years after symptom onset | Early biomarker testing could be paired with treatment initiation | | Median survival (FTD) | 6–8 years post‑diagnosis | If disease progression slows by 30% (as suggested by animal models), median survival could extend to ~9–10 years | | Healthcare costs (U.S.) | $15 B annually (direct + indirect) | Potential 15–20% reduction in long‑term care costs if functional decline is delayed |

Beyond pure economics, the quality‑of‑life benefits—maintaining independence, preserving language, and reducing caregiver burden—are arguably the most compelling outcome.